Yōni.Fit received 510(k) clearance from the US Food and Drug Administration (FDA) in August 2024 following completion of a national clinical trial by Urogynecologists at Stanford, NYU, and Jefferson Health.
“Watkins-Conti has taken the steps necessary to protect its IP assets to ensure that it will have the exclusive right to commercialize its Yōni.Fit device, and to assert or defend the company’s legal rights against others if either ever becomes necessary. Exclusivity is essential in getting the product out to women who need the help that only Watkins-Conti can provide.”
Jennie Martel – Chief of Global Brand Protection, Colgate-Palmolive
